1002126-70-6

Basic information

• Product Name: (2E,4Z)-N-(3-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienamide
• CAS NO: 1002126-70-6
• Molecular Weight: 550.534
• Mol File: 1002126-70-6.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (2E,4Z)-N-(3-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienamide(CAS DataBase Reference)
• NIST Chemistry Reference: (2E,4Z)-N-(3-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienamide(1002126-70-6)
• EPA Substance Registry System: (2E,4Z)-N-(3-hydroxy-2-oxo-1,2,3,4-tetrahydro-5-quinolyl)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienamide(1002126-70-6)

Safety Data

• Hazardous Substances Data: 1002126-70-6(Hazardous Substances Data)

Upstream product

• 106-41-2 4-bromo-phenol 
• 1002127-25-4 ethyl (2E,4Z)-5-bromo-5-(4-trifluoromethylphenyl)-2,4-pentadienoate 
• 1369534-98-4 ethyl (2E,4Z)-5-[4-(oxetan-3-yloxy)phenyl]-5-(4-trifluoromethylphenyl)-2,4-pentadienoate 
• 1369534-97-3 ethyl (2E,4E)-5-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)-5-(4-trifluoromethylphenyl)-2,4-pentadienoate 
• 1369534-96-2 3-(4-bromophenoxy)oxetane 
• 1369534-95-1 2-(4-bromophenoxy)-3-tosyloxy-1-propanol 
• 1002129-40-9 C₂₁H₁₇F₃O₄ 
• 292143-04-5 5-amino-3-hydroxy-3,4-dihydroquinolin-2(1H)-one 
• 1369534-94-0 2-(4-bromophenoxy)-1,3-diacetoxypropane 

Relevant articles and documents

Discovery of novel 5,5-diarylpentadienamides as orally available transient receptor potential vanilloid 1 (TRPV1) antagonists

We have developed a novel and potent chemical series of 5,5-diphenylpentadienamides for targeting TRPV1 in vitro and in vivo. In this investigation, we examined a variety of replacements for the 5-position of dienamides with the goal of addressing issues related to pharmacokinetics. Our data suggest that substitution with alkoxy groups on the phenyl ring at the 5-position increases their ability to penetrate the blood-brain barrier. This investigation culminated in the discovery of compound (R)-36b, which showed a good pharmacokinetic profile. In vivo, compound (R)-36b was found to be effective at reversing mechanical allodynia in rats in a dose-dependent manner, and it reversed thermal hyperalgesia in a model of neuropathic pain induced by sciatic nerve injury.